Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ADMA Biologics Inc (ADMA : NSDQ)
 
 • Company Description   
ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.

Number of Employees: 527

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.05 Daily Weekly Monthly
20 Day Moving Average: 2,981,909 shares
Shares Outstanding: 195.92 (millions)
Market Capitalization: $401.64 (millions)
Beta: 1.07
52 Week High: $2.16
52 Week Low: $1.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.99% 14.88%
12 Week 30.57% 43.56%
Year To Date 45.39% 77.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
465 STATE ROUTE 17
-
RAMSEY,NJ 07446
USA
ph: 201-478-5552
fax: 201-478-5553
info@admabio.com http://www.admabiologics.com
 
 • General Corporate Information   
Officers
Adam S. Grossman - President and Chief Executive Officer
Steven A. Elms - Chairman
Jerrold B. Grossman - Vice Chairman
Brian Lenz - Executive Vice President and Chief Financial Offic
Martha J. Demski - Director

Peer Information
ADMA Biologics Inc (CORR.)
ADMA Biologics Inc (RSPI)
ADMA Biologics Inc (CGXP)
ADMA Biologics Inc (BGEN)
ADMA Biologics Inc (GTBP)
ADMA Biologics Inc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 000899104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 195.92
Most Recent Split Date: (:1)
Beta: 1.07
Market Capitalization: $401.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.16
Price/Cash Flow: -
Price / Sales: 4.27
EPS Growth
vs. Year Ago Period: 37.50%
vs. Previous Quarter: -11.11%
Sales Growth
vs. Year Ago Period: 81.34%
vs. Previous Quarter: 10.31%
ROE
03/31/22 - -59.36
12/31/21 - -61.23
09/30/21 - -71.69
ROA
03/31/22 - -27.13
12/31/21 - -29.14
09/30/21 - -32.53
Current Ratio
03/31/22 - 7.60
12/31/21 - 6.87
09/30/21 - 5.41
Quick Ratio
03/31/22 - 3.19
12/31/21 - 2.77
09/30/21 - 1.88
Operating Margin
03/31/22 - -76.18
12/31/21 - -88.51
09/30/21 - -108.60
Net Margin
03/31/22 - -83.27
12/31/21 - -88.51
09/30/21 - -108.60
Pre-Tax Margin
03/31/22 - -83.27
12/31/21 - -88.52
09/30/21 - -108.60
Book Value
03/31/22 - 0.65
12/31/21 - 0.72
09/30/21 - 0.74
Inventory Turnover
03/31/22 - 0.73
12/31/21 - 0.74
09/30/21 - 0.78
Debt-to-Equity
03/31/22 - 1.15
12/31/21 - 0.72
09/30/21 - 0.99
Debt-to-Capital
03/31/22 - 53.44
12/31/21 - 42.02
09/30/21 - 49.63
 

Powered by Zacks Investment Research ©